TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05125731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental absence
Description: Parent does not accompany the child during dental treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental visual support
Description: The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental presence
Description: Parent accompanies the child during dental treatment
Study: NCT05220553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROLIMB Prosthesis
Description: Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
Study: NCT05680870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
Study: NCT05387148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
Study: NCT04771234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital self-guided CBT-i
Description: A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
Study: NCT05967819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Stress
Description: Increased exercise volume

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Stress
Description: Increased exercise volume

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Stress
Description: cognitive tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Stress
Description: cognitive tasks
Study: NCT05827393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle transplantation
Description: the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle transplantation
Description: the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
Study: NCT06542133

Intervention type: DEVICE
Intervention: AVEIR remote care system
Description: In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
Study: NCT06391619

Intervention type: OTHER
Intervention: No intervention
Description: Study is observational

Intervention type: OTHER
Intervention: No intervention
Description: Study is observational
Study: NCT05598151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM97662
Description: To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
Study: NCT05076318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aminoacid, alanine-infusion
Description: During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
Study: NCT06354283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
Study: NCT01132794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: 1mcg per kg dexmedetomidine given intranasally 45 minutes before operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal nasal saline
Study: NCT05211544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy modalities and exercise
Description: 30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping and exercise
Description: 30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
Study: NCT06257693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
Study: NCT06127836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG guided sentinel lymph node biopsy
Description: The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
Study: NCT05991908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, busulfan and melphalan
Description: FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and Busulfan
Description: FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
Study: NCT04576741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bMBI standard practice
Description: This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
Study: NCT06174662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music
Description: The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
Study: NCT06556160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode
Description: During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered.
Study: NCT05132972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normoxic Allogenic UCMSC
Description: Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline solution
Description: Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
Study: NCT04821648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJV001
Description: Subcutaneous injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJV001
Description: Subcutaneous injection in the abdomen
Study: NCT06556160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode
Description: During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered.
Study: NCT04821648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJV001
Description: Subcutaneous injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
Study: NCT05041491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREAK
Description: The BREAK intervention is a physical activity regimen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ONE
Description: The ONE intervention is a physical activity regimen.
Study: NCT04877834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
Study: NCT05677438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-498 dose#1
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-498 dose#2
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-498 dose#3
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CKD-498 dose#1
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#1
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#1
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CKD-498 dose#2
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#2
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#2
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CKD-498 dose#3
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#3
Description: oral, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of CKD-498 dose#3
Description: oral, once daily, 24 weeks
Study: NCT05692908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Study: NCT04911439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Arousal
Description: This group will see affective images of the International Affective Picture System with low arousal level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium arousal
Description: This group will see affective images of the International Affective Picture System with medium arousal level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High arousal
Description: This group will see affective images of the International Affective Picture System with high arousal level
Study: NCT06176924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Description: Relaxation technique

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation technique
Description: Relaxation technique
Study: NCT05700513

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules containing the combination products
Description: Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules containing maltodextrin
Study: NCT04852302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Therapy
Description: The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
Study: NCT05397223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD®
Description: adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile lyophilized product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile lyophilized product
Study: NCT05790291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: the experimental group will practice using the checklist
Study: NCT06079983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: Administered intravenously according to protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine hydrochloride for injection
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine tartrate injection
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel for injection (albumin-bound type)
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin mesylate injection
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT05853523

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gas ozone
Description: The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
Study: NCT06557980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: toothpaste
Description: group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: toothpaste
Description: group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
Study: NCT04941859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupoint massage and application
Description: Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
Study: NCT05853523

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Diode laser and desensitized gel
Description: The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel.
Study: NCT05759403

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical excitability using transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical excitability using transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
Study: NCT05399654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-001
Description: TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
Study: NCT05964101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
Study: NCT05781789

Intervention type: OTHER
Intervention: Telehealth for preoperative evaluation
Description: Conduct of preoperative evaluation remotely using Zoom application

Intervention type: OTHER
Intervention: Telehealth for preoperative evaluation
Description: Conduct of preoperative evaluation remotely using Zoom application
Study: NCT05244486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX 1-6 months (randomized phase)
Description: Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RestoreX 6-9 months (open label phase)
Description: Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX 6-9 months (open label phase)
Description: Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
Study: NCT05106517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60mg/6 months subcutaneously + placebo iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Iv zoledronic acid and placebo /6 months subcutaneously